IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Quick facts
Marketed products
- albuterol plus tiotropium · Respiratory/Pulmonology
Albuterol and tiotropium work together as a combination bronchodilator therapy: albuterol provides rapid short-acting relief by stimulating beta-2 adrenergic receptors, while tiotropium provides sustained long-acting bronchodilation by blocking muscarinic M3 receptors.
Phase 3 pipeline
- Anastrozole or Letrozole or Exemestane · Oncology
These aromatase inhibitors block the enzyme aromatase to reduce estrogen production in postmenopausal women with hormone receptor-positive breast cancer. - antidiabetics · Metabolic
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy portfolio CI brief
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy pipeline updates RSS
Frequently asked questions about IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
What are IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy's marketed drugs?
Top marketed products include albuterol plus tiotropium.
What is IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy's pipeline?
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy has 2 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include Anastrozole or Letrozole or Exemestane, antidiabetics.
Related
- albuterol plus tiotropium · Respiratory/Pulmonology
- Sector hub: All tracked pharma companies